IONS
Ionis Pharmaceuticals, Inc.$71.53-0.70 (-0.98%)Prev Close$72.23·MCap$12.35B·P/E—·Vol1.60M·Yield—
▲
Buys (12M)
1
$477.9K
▼
Sells (12M)
99
$162.36M
◆
Net Activity
Net Seller
$161.88M
●
Active Insiders
19
last 12 mo
Over the past 12 months, insider activity at Ionis Pharmaceuticals, Inc. (IONS) has been dominated by selling, with 1 insider purchase totaling $477.9K and 99 insider sales totaling $162.36M. The most recent insider transaction was by PARSHALL B LYNNE (director), who sold $381.4K worth of shares on Apr 17, 2026. Ionis Pharmaceuticals, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $12.35B.
IONS Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 17, 2026 | PARSHALL B LYNNE | director | Sell | 5,000 | $76.27 | $381.4K | 51,878 |
| Apr 17, 2026 | Jenne Kyle | officer: EVP, Chf GL Pdt Str Ofcr | Sell | 4,902 | $75.17 | $368.5K | 23,713 |
| Apr 17, 2026 | Baroldi Joseph | officer: EVP, Chief Business Officer | Sell | 5,619 | $74.56 | $419.0K | 46,535 |
| Apr 17, 2026 | Birchler Brian | officer: EVP, Corp and Development Ops | Sell | 973 | $75.04 | $73.0K | 67,500 |
| Apr 2, 2026 | Devers Shannon L. | officer: EVP, Chief Human Resources Ofc | Sell | 6,193 | $74.05 | $458.6K | 16,348-27% |
| Apr 2, 2026 | KLEIN JOSEPH III | director | Sell | 22,321 | $75.55 | $1.69M | 13,230-63% |
| Mar 23, 2026 | Schneider Eugene | officer: EVP, Chf Clinical Develop Ofcr | Sell | 5,812 | $70.97 | $412.5K | 63,890 |
| Mar 18, 2026 | HOUGEN ELIZABETH L | officer: EVP, Finance & CFO | Sell | 225,220 | $72.43 | $16.31M | 102,272-69% |
| Mar 5, 2026 | Baroldi Joseph | officer: EVP, Chief Business Officer | Sell | 6,421 | $79.73 | $511.9K | 41,317 |
| Mar 5, 2026 | BENNETT C FRANK | officer: EVP, Chief Scientific Officer | Sell | 85,089 | $79.23 | $6.74M | 94,043-48% |
| Mar 5, 2026 | Devers Shannon L. | officer: EVP, Chief Human Resources Ofc | Sell | 20,106 | $79.40 | $1.60M | 28,326-42% |
| Mar 5, 2026 | Diaz Allene M. | director | Sell | 54,878 | $79.35 | $4.35M | 19,424-74% |
| Mar 5, 2026 | KLEIN JOSEPH III | director | Sell | 21,332 | $79.51 | $1.70M | 18,820-53% |
| Mar 5, 2026 | LOSCALZO JOSEPH | director | Sell | 1,032 | $80.26 | $82.8K | 36,330 |
| Feb 13, 2026 | PARSHALL B LYNNE | director | Sell | 5,000 | $82.72 | $413.6K | 56,344 |
| Feb 13, 2026 | Swayze Eric | officer: EVP Research | Sell | 31,284 | $81.76 | $2.56M | 38,312-45% |
| Feb 11, 2026 | PARSHALL B LYNNE | Director | Sell | 5,000 | $82.72 | $413.6K | 0 |
| Feb 10, 2026 | Monia Brett P | director, officer: Chief Executive Officer | Sell | 29,430 | $85.79 | $2.52M | 254,497 |
| Feb 6, 2026 | Monia Brett P | Chief Executive Officer | Sell | 29,430 | $85.79 | $2.52M | 0 |
| Feb 4, 2026 | BENNETT C FRANK | officer: EVP, Chief Scientific Officer | Sell | 36,463 | $82.79 | $3.02M | 80,293-31% |
| Feb 2, 2026 | Baroldi Joseph | officer: EVP, Chief Business Officer | Sell | 5,296 | $82.96 | $439.4K | 45,413 |
| Feb 2, 2026 | BENNETT C FRANK | officer: EVP, Chief Scientific Officer | Sell | 90,974 | $82.93 | $7.54M | 100,293-48% |
| Feb 2, 2026 | Birchler Brian | officer: EVP, Corp and Development Ops | Sell | 6,179 | $83.03 | $513.0K | 66,247 |
| Feb 2, 2026 | HOUGEN ELIZABETH L | officer: EVP, Finance & CFO | Sell | 6,988 | $83.24 | $581.7K | 132,881 |
| Feb 2, 2026 | Monia Brett P | director, officer: Chief Executive Officer | Sell | 62,970 | $82.72 | $5.21M | 283,927 |
| Feb 2, 2026 | O'NEIL PATRICK R. | officer: EVP CLO & General Counsel | Sell | 6,179 | $83.53 | $516.2K | 71,983 |
| Feb 2, 2026 | Schneider Eugene | officer: EVP, Chf Clinical Develop Ofcr | Sell | 6,179 | $83.45 | $515.6K | 69,702 |
| Feb 2, 2026 | Swayze Eric | officer: EVP Research | Sell | 6,179 | $82.93 | $512.4K | 47,747 |
| Jan 29, 2026 | Baroldi Joseph | EVP, Chief Business Officer | Sell | 5,296 | $82.96 | $439.4K | 0 |
| Jan 29, 2026 | BENNETT C FRANK | EVP, Chief Scientific Officer | Sell | 5,885 | $82.95 | $488.1K | 0 |
| Jan 29, 2026 | Birchler Brian | EVP, Corp and Development Ops | Sell | 6,179 | $83.03 | $513.0K | 0 |
| Jan 29, 2026 | HOUGEN ELIZABETH L | EVP, Finance & CFO | Sell | 6,988 | $83.24 | $581.7K | 0 |
| Jan 29, 2026 | Monia Brett P | Chief Executive Officer | Sell | 62,970 | $82.72 | $5.21M | 0 |
| Jan 29, 2026 | O'NEIL PATRICK R. | EVP CLO & General Counsel | Sell | 6,179 | $83.53 | $516.2K | 0 |
| Jan 29, 2026 | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | Sell | 6,179 | $83.45 | $515.6K | 0 |
| Jan 29, 2026 | Swayze Eric | EVP Research | Sell | 6,179 | $82.93 | $512.4K | 0 |
| Jan 23, 2026 | Devers Shannon L. | officer: EVP, Chief Human Resources Ofc | Sell | 3,977 | $81.34 | $323.5K | 22,541 |
| Jan 22, 2026 | Devers Shannon L. | EVP, Chief Human Resources Ofc | Sell | 3,977 | $81.34 | $323.5K | 0 |
| Jan 15, 2026 | Baroldi Joseph | EVP, Chief Business Officer | Sell | 8,056 | $75.75 | $610.3K | 0 |
| Jan 15, 2026 | BENNETT C FRANK | EVP, Chief Scientific Officer | Sell | 8,977 | $75.15 | $674.6K | 0 |
| Jan 15, 2026 | Birchler Brian | EVP, Corp and Development Ops | Sell | 8,480 | $75.11 | $636.9K | 0 |
| Jan 15, 2026 | Devers Shannon L. | EVP, Chief Human Resources Ofc | Sell | 8,353 | $75.95 | $634.4K | 0 |
| Jan 15, 2026 | HOUGEN ELIZABETH L | EVP, Finance & CFO | Sell | 12,922 | $75.22 | $972.0K | 0 |
| Jan 15, 2026 | Jenne Kyle | EVP, Chf GL Pdt Str Ofcr | Sell | 1,823 | $75.96 | $138.5K | 0 |
| Jan 15, 2026 | Kordasiewicz Holly B. | EVP, Chief Development Officer | Sell | 4,141 | $75.66 | $313.3K | 0 |
| Jan 15, 2026 | Monia Brett P | Chief Executive Officer | Sell | 44,034 | $74.82 | $3.29M | 0 |
| Jan 15, 2026 | O'NEIL PATRICK R. | EVP CLO & General Counsel | Sell | 9,191 | $75.84 | $697.0K | 0 |
| Jan 15, 2026 | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | Sell | 9,302 | $75.59 | $703.1K | 0 |
| Jan 15, 2026 | Swayze Eric | EVP Research | Sell | 9,933 | $75.34 | $748.4K | 0 |
| Jan 7, 2026 | Devers Shannon L. | EVP, Chief Human Resources Ofc | Sell | 44,199 | $85.08 | $3.76M | 0 |
Showing 1–50 of 105
1 / 3
IONS Insider Buying Activity
The following table shows recent insider purchases of Ionis Pharmaceuticals, Inc. (IONS) stock reported via SEC Form 4 filings.
No insider buying activity found for IONS in the last 12 months.
IONS Insider Selling Activity
The following table shows recent insider sales of Ionis Pharmaceuticals, Inc. (IONS) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 17, 2026 | PARSHALL B LYNNE | director | Sell | 5,000 | $76.27 | $381.4K | 51,878 |
| Apr 17, 2026 | Jenne Kyle | officer: EVP, Chf GL Pdt Str Ofcr | Sell | 4,902 | $75.17 | $368.5K | 23,713 |
| Apr 17, 2026 | Baroldi Joseph | officer: EVP, Chief Business Officer | Sell | 5,619 | $74.56 | $419.0K | 46,535 |
| Apr 17, 2026 | Birchler Brian | officer: EVP, Corp and Development Ops | Sell | 973 | $75.04 | $73.0K | 67,500 |
| Apr 2, 2026 | Devers Shannon L. | officer: EVP, Chief Human Resources Ofc | Sell | 6,193 | $74.05 | $458.6K | 16,348-27% |
| Apr 2, 2026 | KLEIN JOSEPH III | director | Sell | 22,321 | $75.55 | $1.69M | 13,230-63% |
| Mar 23, 2026 | Schneider Eugene | officer: EVP, Chf Clinical Develop Ofcr | Sell | 5,812 | $70.97 | $412.5K | 63,890 |
| Mar 18, 2026 | HOUGEN ELIZABETH L | officer: EVP, Finance & CFO | Sell | 225,220 | $72.43 | $16.31M | 102,272-69% |
| Mar 5, 2026 | Baroldi Joseph | officer: EVP, Chief Business Officer | Sell | 6,421 | $79.73 | $511.9K | 41,317 |
| Mar 5, 2026 | BENNETT C FRANK | officer: EVP, Chief Scientific Officer | Sell | 85,089 | $79.23 | $6.74M | 94,043-48% |
| Mar 5, 2026 | Devers Shannon L. | officer: EVP, Chief Human Resources Ofc | Sell | 20,106 | $79.40 | $1.60M | 28,326-42% |
| Mar 5, 2026 | Diaz Allene M. | director | Sell | 54,878 | $79.35 | $4.35M | 19,424-74% |
| Mar 5, 2026 | KLEIN JOSEPH III | director | Sell | 21,332 | $79.51 | $1.70M | 18,820-53% |
| Mar 5, 2026 | LOSCALZO JOSEPH | director | Sell | 1,032 | $80.26 | $82.8K | 36,330 |
| Feb 13, 2026 | PARSHALL B LYNNE | director | Sell | 5,000 | $82.72 | $413.6K | 56,344 |
| Feb 13, 2026 | Swayze Eric | officer: EVP Research | Sell | 31,284 | $81.76 | $2.56M | 38,312-45% |
| Feb 11, 2026 | PARSHALL B LYNNE | Director | Sell | 5,000 | $82.72 | $413.6K | 0 |
| Feb 10, 2026 | Monia Brett P | director, officer: Chief Executive Officer | Sell | 29,430 | $85.79 | $2.52M | 254,497 |
| Feb 6, 2026 | Monia Brett P | Chief Executive Officer | Sell | 29,430 | $85.79 | $2.52M | 0 |
| Feb 4, 2026 | BENNETT C FRANK | officer: EVP, Chief Scientific Officer | Sell | 36,463 | $82.79 | $3.02M | 80,293-31% |
| Feb 2, 2026 | Baroldi Joseph | officer: EVP, Chief Business Officer | Sell | 5,296 | $82.96 | $439.4K | 45,413 |
| Feb 2, 2026 | BENNETT C FRANK | officer: EVP, Chief Scientific Officer | Sell | 90,974 | $82.93 | $7.54M | 100,293-48% |
| Feb 2, 2026 | Birchler Brian | officer: EVP, Corp and Development Ops | Sell | 6,179 | $83.03 | $513.0K | 66,247 |
| Feb 2, 2026 | HOUGEN ELIZABETH L | officer: EVP, Finance & CFO | Sell | 6,988 | $83.24 | $581.7K | 132,881 |
| Feb 2, 2026 | Monia Brett P | director, officer: Chief Executive Officer | Sell | 62,970 | $82.72 | $5.21M | 283,927 |
| Feb 2, 2026 | O'NEIL PATRICK R. | officer: EVP CLO & General Counsel | Sell | 6,179 | $83.53 | $516.2K | 71,983 |
| Feb 2, 2026 | Schneider Eugene | officer: EVP, Chf Clinical Develop Ofcr | Sell | 6,179 | $83.45 | $515.6K | 69,702 |
| Feb 2, 2026 | Swayze Eric | officer: EVP Research | Sell | 6,179 | $82.93 | $512.4K | 47,747 |
| Jan 29, 2026 | Baroldi Joseph | EVP, Chief Business Officer | Sell | 5,296 | $82.96 | $439.4K | 0 |
| Jan 29, 2026 | BENNETT C FRANK | EVP, Chief Scientific Officer | Sell | 5,885 | $82.95 | $488.1K | 0 |
| Jan 29, 2026 | Birchler Brian | EVP, Corp and Development Ops | Sell | 6,179 | $83.03 | $513.0K | 0 |
| Jan 29, 2026 | HOUGEN ELIZABETH L | EVP, Finance & CFO | Sell | 6,988 | $83.24 | $581.7K | 0 |
| Jan 29, 2026 | Monia Brett P | Chief Executive Officer | Sell | 62,970 | $82.72 | $5.21M | 0 |
| Jan 29, 2026 | O'NEIL PATRICK R. | EVP CLO & General Counsel | Sell | 6,179 | $83.53 | $516.2K | 0 |
| Jan 29, 2026 | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | Sell | 6,179 | $83.45 | $515.6K | 0 |
| Jan 29, 2026 | Swayze Eric | EVP Research | Sell | 6,179 | $82.93 | $512.4K | 0 |
| Jan 23, 2026 | Devers Shannon L. | officer: EVP, Chief Human Resources Ofc | Sell | 3,977 | $81.34 | $323.5K | 22,541 |
| Jan 22, 2026 | Devers Shannon L. | EVP, Chief Human Resources Ofc | Sell | 3,977 | $81.34 | $323.5K | 0 |
| Jan 15, 2026 | Baroldi Joseph | EVP, Chief Business Officer | Sell | 8,056 | $75.75 | $610.3K | 0 |
| Jan 15, 2026 | BENNETT C FRANK | EVP, Chief Scientific Officer | Sell | 8,977 | $75.15 | $674.6K | 0 |
| Jan 15, 2026 | Birchler Brian | EVP, Corp and Development Ops | Sell | 8,480 | $75.11 | $636.9K | 0 |
| Jan 15, 2026 | Devers Shannon L. | EVP, Chief Human Resources Ofc | Sell | 8,353 | $75.95 | $634.4K | 0 |
| Jan 15, 2026 | HOUGEN ELIZABETH L | EVP, Finance & CFO | Sell | 12,922 | $75.22 | $972.0K | 0 |
| Jan 15, 2026 | Jenne Kyle | EVP, Chf GL Pdt Str Ofcr | Sell | 1,823 | $75.96 | $138.5K | 0 |
| Jan 15, 2026 | Kordasiewicz Holly B. | EVP, Chief Development Officer | Sell | 4,141 | $75.66 | $313.3K | 0 |
| Jan 15, 2026 | Monia Brett P | Chief Executive Officer | Sell | 44,034 | $74.82 | $3.29M | 0 |
| Jan 15, 2026 | O'NEIL PATRICK R. | EVP CLO & General Counsel | Sell | 9,191 | $75.84 | $697.0K | 0 |
| Jan 15, 2026 | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | Sell | 9,302 | $75.59 | $703.1K | 0 |
| Jan 15, 2026 | Swayze Eric | EVP Research | Sell | 9,933 | $75.34 | $748.4K | 0 |
| Jan 7, 2026 | Devers Shannon L. | EVP, Chief Human Resources Ofc | Sell | 44,199 | $85.08 | $3.76M | 0 |
IONS Insiders
Similar Stocks to IONS
VRTX
Vertex Pharmaceuticals Incorporated
$429.47+0.81%
$111.71B
REGN
Regeneron Pharmaceuticals, Inc.
$734.06-1.39%
$77.87B
ALNY
Alnylam Pharmaceuticals, Inc.
$303.44-1.64%
$41.24B
INSM
Insmed Incorporated
$135.11-0.64%
$30.79B
RVMD
Revolution Medicines, Inc.
$144.62+9.92%
$29.51B
UTHR
United Therapeutics Corporation
$566.69+0.03%
$25.13B
MRNA
Moderna, Inc.
$47.16-3.17%
$21.42B
RPRX
Royalty Pharma plc
$49.40-0.50%
$21.20B